Since 2016, the FDA has approved a handful of therapies to treat Duchenne muscular dystrophy (DMD). But some uncertainty exists over their effectiveness, in addition to concerns about their costs. Additional products may be available soon, as the pipeline for the condition boasts several candidates.
- Datapoint, Medicare and Medicaid
- Abstract, Health Plans
- People on the Move
- Medicare and Medicaid
- Datapoint, Drug Benefits